Palisade Bio (PALI) Expected to Post Quarterly Earnings on Monday

Key Points

• Palisade Bio is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $0.06 per share and revenue of $0.47 million. The earnings call is scheduled for November 10 at 4:00 p.m. ET.
• In the prior quarter, the company reported a $0.05 per-share loss and $0.50 million in revenue, matching consensus estimates. Analysts expect full-year and next-year losses of $0.22 and $0.28 per share, respectively.
• Shares opened at $1.16, near the 12-month low of $1.10, while analyst sentiment remains mixed but averages a “Buy” rating with a $9.29 price target; Palisade Bio is developing gastrointestinal treatments led by LB1148.

Palisade Bio (NASDAQ:PALI - Get Free Report) will likely be posting its Q3 2026 resultson Monday, November 9th. Analysts expect Palisade Bio to announce earnings of ($0.06) per share and revenue of $0.47 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Palisade Bio (NASDAQ:PALI - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts expect Palisade Bio to post ($0.22) EPS for the current fiscal year and ($0.28) EPS for the next fiscal year.

Palisade Bio Price Performance

Shares of NASDAQ:PALI opened at $1.16 on Monday. Palisade Bio has a 12-month low of $1.10 and a 12-month high of $2.85. The company's 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.85. The firm has a market cap of $202.15 million, a PE ratio of -2.42 and a beta of 1.61.

Analyst Ratings Changes

Several brokerages have weighed in on PALI. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Palisade Bio in a report on Monday, October 12th. Raymond James Financial initiated coverage on Palisade Bio in a research report on Thursday, October 8th. They issued an "outperform" rating and a $6.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Palisade Bio in a research note on Tuesday, October 13th. Wall Street Zen cut shares of Palisade Bio from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Palisade Bio in a research report on Wednesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $9.29.

About Palisade Bio

Palisade Bio, Inc NASDAQ: PALI is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and complications associated with gastrointestinal surgery. The company's research is centered on treatments intended to protect the intestinal barrier and support recovery following major medical procedures.

Palisade Bio's lead product candidate, LB1148, is an orally administered serine protease inhibitor designed to reduce the harmful effects of digestive enzymes released during surgery or gastrointestinal injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.